An underground market for unapproved weight-loss drugs is being driven by social media fitness personalities and sellers on messaging platforms, based on new investigations.
Experimental Treatment Acquiring Popularity Via Social Media
The experimental drug, which is still in research studies, is being promoted by social media influencers for its alleged weight-reducing effects. Followers are encouraged to message these accounts privately for source information, while also receiving promotional offers.
Active Trade on Social Networks
Additionally, a flourishing market exists on messaging services, where groups with thousands of participants share “before and after” images, injection guides and assertions of next-day British shipping. Vendors market the substance there before redirecting buyers to other platforms for transactions.
Learning About The Experimental Drug
This medication is an investigational injectable developed by American pharmaceutical company Eli Lilly. The drug affects three intestinal hormones – GLP-1, GIP and pancreatic hormone. Early trials suggest it could help individuals lose up to 25% of their total weight. Referred to as the “triple G”, the substance is being promoted online as the next Ozempic.
Medical Experts Express Concerns
However, doctors and pharmacists have warned that the distribution of what is still an unapproved drug in the United Kingdom is a cause for concern and could lead to users injecting products of unknown origin.
Some experts stated the popularity for retatrutide could be connected to the increasing price of approved weight loss treatments such as Mounjaro.
Regulatory Position and Implementation
Marketing the unapproved drug on social media or messaging apps is prohibited in the United Kingdom, as it is an unapproved medication that must not be marketed or supplied for personal consumption under the Human Medicines Regulations 2012.
Some content creators attempt to sidestep the rules by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled drug, but promotion and supply can still breach medicines, advertising, and consumer regulations, risking penalties, prosecution or prison.
Service Reaction and Material Elimination
Based on the social media company, the service has taken down problematic content and prohibited related keywords and search suggestions. The company stated it was dedicated to maintaining the service secure and investing in enhancing compliance measures.
Online Marketplace Activities
Investigations also discovered communities with up to 9,000 members marketing retatrutide using the platform's built-in discovery tool, which operates like a online catalog. Entering “retatrutide” immediately displays groups with thousands of members, populated with photos of weight loss, glowing reviews and detailed instructions for preparing or administering at residence.
Within moments of joining one group, a seller shared WhatsApp details, where the majority of purchases take place. The seller provided an instruction manual and guaranteed delivery within 48 hours. When questioned whether the product was genuine, one vendor said: “You can’t be sure.” Another shared a image of a supposed testing documentation. None inquired about body mass, health issues or past usage.
Item Details and Costs
Inside these groups, posts display dark colored parcels with Royal Mail labels, claiming to contain fresh supplies. One message stated: “It took eight of us to load them this morning.”
Customers can choose between powder vials, prepared at residence with purified liquid, or pre-filled injectors usually sold at 160 pounds for 20mg. When asked how long a injector should be used, sellers give conflicting responses varying between a few weeks to “depends on your body”.
Platform Oversight and Safety Measures
A representative for the messaging service stated it regularly monitored dangerous content on its service including material that promoted the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.
Medical Professional Cautions
“Individuals are injecting substances they cannot confirm. Although the science behind this drug is sound, these digital versions may not include what they advertise,” said a pharmacy expert, the head of pharmaceutical services at Chemist4U.
A medical professional of Asda Online Doctor connected the increase in demand to recent cost increases for approved weight-loss medications such as Mounjaro. “With costs rising, patients are using online platforms. But fake injections are highly risky. You can’t be certain what’s contained or whether the conditions they were produced in was sterile,” she said.
Her staff has already encountered individuals harmed by personal administration from unconfirmed sources. “We understand the disappointment, but buying from messaging apps or WhatsApp is taking chances with your well-being,” said Wyllie. “These materials could be impure or incorrectly dosed.”
Manufacturer Position
A spokesperson from Eli Lilly stated the substance was in third stage clinical trials and had not been reviewed or approved by any regulatory agency globally. “Therefore at this time no one can sell [it] for human use,” they explained, noting that any item “misleadingly claiming itself as a company experimental product not yet approved … may expose users to possibly significant medical dangers”.
